J-BAF study Evaluation of the efficacy and safety of Bepridil hydrochloride in the conversion of persistent atrial fibrillation.A placebo-controlled, randomized, double-blind study. - JBEP-DBT

Bepridil central office0 个研究点目标入组 20 人开始时间: 2006年2月15日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•Persistent AF lasting 7 days or longer by electrocardiogram in term of the surveillance

•1)Persistent AF lasting 1 year or longer.
•2)Cardiac surgery, myocardial infarction within 1 month of the onset or unstable clinical manifestation.
•3)AF because of underlying disease or complications as follows; sick sinus syndrome, giant left atrium, AF with disturbances of conduction, hyperthyrea, mitral stenosis.
•4)left ventricular ejection fraction <= 40%, or heart failure level III orIV at New York Heart Association classification of cardiac performance.
•5)Bradyasystolic AF.
•6)marked QT increased.
•7)a history of syncope because of polymorphic ventricular tachycardia or antiarrhythmic agent.
•8)very low blood pressure
•9)Contraindication for anticoagulation therapy
•10)Severe liver and/or kidney dysfunction
•11)a history of Bepridil
•12)a history of administrated other CTM
•13)females of known or suspected pregnancy
•14)Patients disqualified participating this trial by Dr.

发起方

Bepridil central office